Gedeon Richter Plc. launches Bromokriptin-Richter tablets
Gedeon Richter Plc. has introduced Bromokriptin-Richter 2.5 mg tablets. The medication contains bromocriptine as its active substance.
European pharmaceutical company Gedeon Richter Plc. has launched Bromokriptin-Richter 2.5 mg tablets. The drug contains bromocriptine, a substance used to treat various conditions related to elevated hormone levels.
Bromocriptine belongs to drug classes used for gynecological conditions and as a dopamine receptor agonist. It is prescribed for patients with conditions caused by elevated prolactin or growth hormone levels, which can stem from various causes including pituitary disorders or medication side effects.
The medication also serves in the treatment of Parkinson's disease due to its dopaminergic effects, suitable for monotherapy or in combination with levodopa. Additionally, it is indicated for certain gynecological issues like menstrual cycle irregularities and female infertility associated with high prolactin levels.
The tablets are intended for adults and adolescents aged 7 and older. Contraindications include hypersensitivity to bromocriptine or ergot alkaloids, uncontrolled hypertension, or a history of hypertension during pregnancy. Patients should consult with a healthcare professional before use.